KR20240112283A - Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법 - Google Patents

Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법 Download PDF

Info

Publication number
KR20240112283A
KR20240112283A KR1020247018494A KR20247018494A KR20240112283A KR 20240112283 A KR20240112283 A KR 20240112283A KR 1020247018494 A KR1020247018494 A KR 1020247018494A KR 20247018494 A KR20247018494 A KR 20247018494A KR 20240112283 A KR20240112283 A KR 20240112283A
Authority
KR
South Korea
Prior art keywords
compound
iii
formula
solid
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018494A
Other languages
English (en)
Korean (ko)
Inventor
안드레 레스카르보
알레산드로 보에지오
수렌드라 피. 싱
칭린 처
쓰이 장
훙옌 허
추샹 저우
자자 저우
위안 린
웨이 구
민 루
윈페이 저우
시졘 궁
시?? 궁
자후이 천
샤오훙 왕
창보 인
Original Assignee
릴레이 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 릴레이 테라퓨틱스, 인크. filed Critical 릴레이 테라퓨틱스, 인크.
Publication of KR20240112283A publication Critical patent/KR20240112283A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247018494A 2021-11-03 2022-11-03 Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법 Pending KR20240112283A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263474P 2021-11-03 2021-11-03
CNPCT/CN2021/128533 2021-11-03
US63/263,474 2021-11-03
CN2021128533 2021-11-03
PCT/US2022/079221 WO2023081757A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Publications (1)

Publication Number Publication Date
KR20240112283A true KR20240112283A (ko) 2024-07-18

Family

ID=86242193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018494A Pending KR20240112283A (ko) 2021-11-03 2022-11-03 Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법

Country Status (12)

Country Link
EP (1) EP4426314A4 (https=)
JP (1) JP2024540303A (https=)
KR (1) KR20240112283A (https=)
CN (1) CN118401245A (https=)
AU (1) AU2022381187A1 (https=)
CA (1) CA3236861A1 (https=)
CL (1) CL2024001364A1 (https=)
IL (1) IL312466A (https=)
MX (1) MX2024005429A (https=)
PE (1) PE20250676A1 (https=)
TW (1) TW202334136A (https=)
WO (1) WO2023081757A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4143196A4 (en) 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF
WO2024055992A1 (zh) * 2022-09-14 2024-03-21 南京再明医药有限公司 三环化合物及其应用
TW202541794A (zh) 2022-11-02 2025-11-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
PE20161323A1 (es) * 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2020173935A1 (en) * 2019-02-26 2020-09-03 Boehringer Ingelheim International Gmbh New isoindolinone substituted indoles and derivatives as ras inhibitors
EP4143196A4 (en) * 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
CA3236861A1 (en) 2023-05-11
JP2024540303A (ja) 2024-10-31
EP4426314A4 (en) 2025-10-01
WO2023081757A1 (en) 2023-05-11
EP4426314A1 (en) 2024-09-11
AU2022381187A1 (en) 2024-05-16
CN118401245A (zh) 2024-07-26
PE20250676A1 (es) 2025-03-04
TW202334136A (zh) 2023-09-01
IL312466A (en) 2024-06-01
CL2024001364A1 (es) 2024-10-25
MX2024005429A (es) 2024-05-21

Similar Documents

Publication Publication Date Title
JP7187729B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
EP4025574B1 (en) Rip1 inhibitory compounds and methods for making and using the same
WO2023060262A1 (en) Pi3k-alpha inhibitors and methods of use thereof
KR20240112283A (ko) Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법
CA3154862A1 (en) Shp2 phosphatase inhibitors and methods of making and using the same
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
CN119060066A (zh) 取代的芳基或杂芳基并双环类抑制剂及其制备方法和应用
AU2021383928A1 (en) Fgfr inhibitors and methods of making and using the same
CN110461853A (zh) 苯并噻吩雌激素受体调节剂
JP2022516685A (ja) ホスファターゼ結合化合物およびそれらを使用する方法
KR20250024871A (ko) PI3Kα 억제제 및 이의 이용 방법
EP4426286A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
CN118201896A (zh) PI3K-α抑制剂和其使用方法
TW202527954A (zh) PI3Kα抑制劑及其製造與使用方法
WO2024151930A1 (en) Pi3k inhibitors and methods of making and using the same
US20260125374A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
CN118251217A (zh) PI3Kα抑制剂及其使用方法
JPWO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
EA051309B1 (ru) Ингибиторы pi3k-альфа и способы их получения и использования
CN121698888A (zh) 取代杂芳基并噻吩类抑制剂及其制备方法和应用
WO2026037254A1 (zh) 作为mrgprx2拮抗剂的化合物
HK40074209A (en) Shp2 phosphatase inhibitors and methods of making and using the same
HK40068242A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40068242B (en) Rip1 inhibitory compounds and methods for making and using the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000